18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool compound...
02:46 , Mar 24, 2018 |  BioCentury  |  Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
22:25 , Jan 5, 2018 |  BioCentury  |  Finance

Building Sosei’s base

Sosei Group Corp. (Tokyo:4565) is tipping the scales towards international, institutional investors as it looks to build a shareholder base that can support the biotech as it begins to bring its first internally discovered candidates...
19:43 , Apr 7, 2017 |  BC Week In Review  |  Company News

Sosei, AstraZeneca milestone payment

Sosei’s Heptares Therapeutics subsidiary will receive a $12 million milestone payment from AstraZeneca under a 2015 deal granting AZ exclusive, worldwide rights to develop and commercialize AZD4635 (see BioCentury, Aug. 10, 2015). The payment was...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Sosei, AstraZeneca deal

Sosei’s Heptares Therapeutics subsidiary received a $10 million milestone payment from AstraZeneca under a 2015 deal granting AZ exclusive, worldwide rights to develop and commercialize HTL1071 ( AZD4635), an adenosine A2A ( ADORA2A) receptor...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Durvalumab: Phase I started

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565, Tokyo, Japan) said AstraZeneca began an open-label, dose-escalation, U.S. Phase I trial to evaluate twice-daily oral HTL1071 ( AZD4635) and in combination...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

AZD4635: Phase I started

Sosei’s Heptares Therapeutics Ltd. subsidiary said AstraZeneca began an open-label, dose-escalation, U.S. Phase I trial to evaluate twice-daily oral HTL1071 alone and in combination with IV durvalumab ( MEDI4736) every 4 weeks in about...
07:00 , Apr 11, 2016 |  BioCentury  |  Finance

Monetizing M&A

In just over a year, Sosei Group Corp. (Tokyo:4565) has nearly got back the $180 million in upfront cash it shelled out to buy Heptares Therapeutics Ltd. based on upfront payments and equity investments from...
07:00 , Aug 17, 2015 |  BioCentury  |  Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Sosei, AstraZeneca deal

Sosei’s Heptares Therapeutics Ltd. subsidiary granted AstraZeneca exclusive, worldwide rights to develop and commercialize cancer candidate HTL1071, an adenosine A2A ( ADORA2A) receptor inhibitor, and other preclinical A2A receptor inhibitors discovered under a...